The most recent study on vitiligo’s prevalence in Egypt was published from Damanhour University in 2020. The study showed ... and children ages 12 and up for treatment. In a statement issued ...

Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a ...

A man who developed vitiligo as a child said he would not use a controversial treatment that may come to the UK. Ruxolitinib works by removing white patches, but carries some potentially serious ...

"This proof-of-concept randomized clinical trial highlighted the efficacy of combining the JAK1/JAK2 inhibitor baricitinib with narrowband UVB in the treatment of adults with active vitiligo," the ...